Jefferies puts Endo on hold

Jefferies & Co., Inc. analyst David Windley rated Endo Pharmaceuticals Holdings, Inc. at hold after the company missed a lowered revenue forecast by $4.5 million, or 2%. The company may have to heavily invest in its new product, Opana, and two late-stage compounds addressing menstrual-related migraine and break-through cancer pain, over the coming quarters, the analyst said. Jefferies' revised its 2007 earnings per share down 2 cents to $1.73, well below consensus of $1.87. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down 9 cents, or 0.31%, at $29.39. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.